IN2014DN09261A - - Google Patents

Info

Publication number
IN2014DN09261A
IN2014DN09261A IN9261DEN2014A IN2014DN09261A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A IN 9261DEN2014 A IN9261DEN2014 A IN 9261DEN2014A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A
Authority
IN
India
Prior art keywords
genomic locus
target genomic
compositions
methods
homologous recombination
Prior art date
Application number
Inventor
David Frendewey
Wojtek Auerbach
David M Valenzuela
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IN2014DN09261A publication Critical patent/IN2014DN09261A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double- strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.
IN9261DEN2014 2012-04-25 2013-04-25 IN2014DN09261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638267P 2012-04-25 2012-04-25
PCT/US2013/038165 WO2013163394A1 (en) 2012-04-25 2013-04-25 Nuclease-mediated targeting with large targeting vectors

Publications (1)

Publication Number Publication Date
IN2014DN09261A true IN2014DN09261A (en) 2015-07-10

Family

ID=48289700

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9261DEN2014 IN2014DN09261A (en) 2012-04-25 2013-04-25

Country Status (19)

Country Link
US (2) US9834786B2 (en)
EP (1) EP2847335B1 (en)
JP (1) JP6275120B2 (en)
KR (1) KR101904508B1 (en)
CN (2) CN109536526B (en)
AU (1) AU2013251558B2 (en)
BR (1) BR112014026294B1 (en)
CA (1) CA2869016C (en)
CY (1) CY1120572T1 (en)
DK (1) DK2847335T3 (en)
ES (1) ES2683071T3 (en)
IL (1) IL234905B (en)
IN (1) IN2014DN09261A (en)
MX (1) MX362523B (en)
PL (1) PL2847335T3 (en)
PT (1) PT2847335T (en)
RU (1) RU2645475C2 (en)
SG (2) SG11201406547YA (en)
WO (1) WO2013163394A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
SI3401400T1 (en) 2012-05-25 2019-10-30 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CN109913495B (en) 2013-02-20 2022-11-25 瑞泽恩制药公司 Genetic modification of rats
SG10201808935WA (en) * 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
ES2844174T3 (en) * 2013-09-18 2021-07-21 Kymab Ltd Methods, cells and organisms
KR101566498B1 (en) * 2013-11-13 2015-11-06 건국대학교 산학협력단 Interleukin 2 receptor gamma gene targeting vector, production of SCID-like miniature pigs by TALEN-mediated gene targeting and use thereof
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
JP6174811B2 (en) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Methods and compositions for targeted genomic modification
SMT201800653T1 (en) 2013-12-11 2019-01-11 Regeneron Pharma Methods and compositions for the targeted modification of a genome
MX385689B (en) 2014-06-06 2025-03-18 Regeneron Pharma METHODS AND COMPOSITIONS FOR MODIFYING A DIRECTED LOCUS.
WO2015200805A2 (en) * 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
EP3561052A1 (en) 2014-10-15 2019-10-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
ES2731437T3 (en) 2014-11-21 2019-11-15 Regeneron Pharma Methods and compositions for directed genetic modification through the use of guide RNA pairs
MX388784B (en) * 2014-12-19 2025-03-20 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.
IL274285B (en) 2015-03-16 2022-07-01 Regeneron Pharma Non-human animals exhibiting reduced upper and lower motor neuron function and sensory perception
KR102377189B1 (en) 2015-05-29 2022-03-22 리제너론 파마슈티칼스 인코포레이티드 Non-human animals having a disruption in a c9orf72 locus
EP3518667B1 (en) 2016-09-30 2024-10-30 Regeneron Pharmaceuticals, Inc. Rodents having a hexanucleotide repeat expansion in a c9orf72 locus
IL271561B2 (en) 2017-06-27 2025-08-01 Regeneron Pharma Non-human animals containing a human ASGR1 site
WO2019028029A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
JP2020533957A (en) 2017-07-31 2020-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． CRISPR Reporter Non-Human Animals and Their Use
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
KR102444458B1 (en) 2017-11-10 2022-09-19 리제너론 파마슈티칼스 인코포레이티드 Non-Human Animals Containing the SLC30A8 Mutation and Methods of Use
CA3076377A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
CN116349651A (en) 2018-03-19 2023-06-30 瑞泽恩制药公司 Transcriptional modulation in animals using the CRISPR/Cas system
US20220053741A1 (en) 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
CN113423831B (en) 2018-12-20 2023-03-10 瑞泽恩制药公司 nuclease-mediated repeat expansion
CN117178959A (en) 2019-04-04 2023-12-08 瑞泽恩制药公司 Non-human animals including the humanized coagulation factor 12 locus
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (en) 2019-06-07 2022-04-06 Regeneron Pharma NON-HUMAN ANIMALS COMPRISING A HUMANIZED ALBUMIN LOCUS.
RU2722933C1 (en) * 2019-06-11 2020-06-05 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Dna protease cutting agent based on cas9 protein from demequina sediminicola bacteria
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
US20230232796A1 (en) 2020-06-26 2023-07-27 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
DE112022001365T5 (en) 2021-03-05 2024-02-15 The Board Of Trustees Of The Leland Stanford Junior University IN VIVO DNA ASSEMBLY AND ANALYSIS
WO2023081847A1 (en) 2021-11-04 2023-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
CN118632622A (en) 2021-12-08 2024-09-10 瑞泽恩制药公司 Mutant myocilin disease model and its use
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
EP4475671A1 (en) 2022-02-07 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
EP4476245A1 (en) 2022-02-11 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
IL317261A (en) 2022-07-29 2025-01-01 Regeneron Pharma Non-human animals comprising a modified transferrin receptor locus
CA3261296A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2024163650A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Animals comprising a modified klhdc7b locus
WO2024189098A1 (en) 2023-03-13 2024-09-19 Iomx Therapeutics Ag Platform technology for the identification of modulators of immune effector cell function
WO2025122754A1 (en) 2023-12-07 2025-06-12 Regeneron Pharmaceuticals, Inc. Gaa knockout non-human animals
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
BR9808584A (en) 1997-03-14 2000-05-23 Idec Pharma Corp Process for integrating genes at specific sites in mammalian cells via homologous recombination and vectors to obtain the same
EP1141360A4 (en) 1998-12-31 2002-11-06 David Gladstone Inst TRANSGENIC RODENTS AND CELL LINES OF RODENTS EXPRESSING HIV CO-RECEPTORS
CA2361191A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
DE60023936T2 (en) * 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
AU2003218382B2 (en) * 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP1581610A4 (en) 2002-09-05 2009-05-27 California Inst Of Techn USE OF CHIMERIC NUCLEASES TO STIMULATE GENE TARGETING
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
AU2004204509A1 (en) * 2003-01-13 2004-07-29 Mario R. Capecchi Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP3222715A1 (en) * 2003-08-08 2017-09-27 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
PL2767161T3 (en) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
FR2879622B1 (en) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech IN VITRO PROCESS FOR THE PRODUCTION OF OOCYTES OR EGGS WITH TARGETED GENOMIC MODIFICATION
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7771967B2 (en) 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
DE602008003684D1 (en) 2007-04-26 2011-01-05 Sangamo Biosciences Inc TARGETED INTEGRATION IN THE PPP1R12C POSITION
SG182144A1 (en) 2007-06-01 2012-07-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
CA2734235C (en) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
US9206404B2 (en) 2008-12-04 2015-12-08 Sangamo Biosciences, Inc. Method of deleting an IgM gene in an isolated rat cell
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2421980A2 (en) 2009-04-23 2012-02-29 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011011678A2 (en) 2009-07-24 2011-01-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
WO2011051390A1 (en) * 2009-10-28 2011-05-05 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Homologous recombination in the oocyte
TR201903376T4 (en) 2009-10-29 2019-04-22 Regeneron Pharma Multifunctional alleles.
US20120315670A1 (en) 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
WO2011068103A1 (en) 2009-12-01 2011-06-09 独立行政法人国立がん研究センター Method for constructing chimeric rat using rat embryonic stem cells
NO2510096T3 (en) 2009-12-10 2015-03-21
CN102791865B (en) 2009-12-21 2015-07-01 凯津公司 Improved techniques for transfecting protoplasts
US9695432B2 (en) 2010-01-22 2017-07-04 Dow Agrosciences Llc Excision of transgenes in genetically modified organisms
WO2011100058A1 (en) * 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
CN103025344B (en) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 Novel DNA-associated proteins and application thereof
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
AU2011265306C1 (en) 2010-06-11 2015-01-22 Regeneron Pharmaceuticals, Inc. Production of fertile XY female animals from XY ES cells
US8945868B2 (en) * 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
WO2012018726A1 (en) * 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
EP2718446A2 (en) 2011-06-07 2014-04-16 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
SMT202100243T1 (en) 2011-10-28 2021-05-07 Regeneron Pharma Genetically modified t cell receptor mice
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
SI3401400T1 (en) 2012-05-25 2019-10-30 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP2858486A4 (en) 2012-06-12 2016-04-13 Hoffmann La Roche METHODS AND COMPOSITIONS FOR GENERATING ALLLETS WITH CONDITIONAL INACTIVATION
CN105188767A (en) 2012-07-25 2015-12-23 布罗德研究所有限公司 Inducible DNA-binding proteins and genome interference tools and their applications
SG11201503059XA (en) 2012-10-23 2015-06-29 Toolgen Inc Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
ES2701749T3 (en) 2012-12-12 2019-02-25 Broad Inst Inc Methods, models, systems and apparatus to identify target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and transmit results thereof
ES2536353T3 (en) 2012-12-12 2015-05-22 The Broad Institute, Inc. Systems engineering, methods and guide compositions optimized for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
BR112015013784A2 (en) 2012-12-12 2017-07-11 Massachusetts Inst Technology application, manipulation and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN113355357B (en) 2012-12-12 2024-12-03 布罗德研究所有限公司 Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN105658796B (en) 2012-12-12 2021-10-26 布罗德研究所有限公司 CRISPR-CAS component systems, methods, and compositions for sequence manipulation
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK3553174T3 (en) 2012-12-17 2025-08-04 Harvard College RNA-GUIDED MODIFICATION OF THE HUMAN GENOME
DK3491915T5 (en) 2012-12-27 2024-09-02 Keygene Nv Method of inducing a targeted translocation in a plant
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
CN109913495B (en) 2013-02-20 2022-11-25 瑞泽恩制药公司 Genetic modification of rats
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
US20140315985A1 (en) 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2016522679A (en) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing with the CRISPR / Cas system
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
EP2986709A4 (en) 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
JP6174811B2 (en) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Methods and compositions for targeted genomic modification
MX385689B (en) 2014-06-06 2025-03-18 Regeneron Pharma METHODS AND COMPOSITIONS FOR MODIFYING A DIRECTED LOCUS.
WO2015200805A2 (en) 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
MX2017000646A (en) 2014-07-15 2017-04-27 Juno Therapeutics Inc GENETICALLY MODIFIED CELLS FOR ADOPTIVE CELL THERAPY.
MX388784B (en) 2014-12-19 2025-03-20 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.

Also Published As

Publication number Publication date
DK2847335T3 (en) 2018-08-13
CN104364380A (en) 2015-02-18
US20130309670A1 (en) 2013-11-21
EP2847335A1 (en) 2015-03-18
BR112014026294A2 (en) 2020-07-07
PT2847335T (en) 2018-09-28
US20180037910A1 (en) 2018-02-08
KR20150004816A (en) 2015-01-13
PL2847335T3 (en) 2019-01-31
SG11201406547YA (en) 2014-11-27
KR101904508B1 (en) 2018-10-04
JP2015514439A (en) 2015-05-21
RU2014145942A (en) 2016-06-10
MX2014012994A (en) 2015-02-04
CN109536526A (en) 2019-03-29
WO2013163394A1 (en) 2013-10-31
CA2869016A1 (en) 2013-10-31
US9834786B2 (en) 2017-12-05
RU2645475C2 (en) 2018-02-21
EP2847335B1 (en) 2018-06-27
US10301646B2 (en) 2019-05-28
SG10201702445TA (en) 2017-04-27
BR112014026294B1 (en) 2021-11-23
CY1120572T1 (en) 2019-07-10
CN109536526B (en) 2020-06-09
HK1207396A1 (en) 2016-01-29
ES2683071T3 (en) 2018-09-24
CN104364380B (en) 2018-10-09
MX362523B (en) 2019-01-22
IL234905B (en) 2018-10-31
JP6275120B2 (en) 2018-02-07
CA2869016C (en) 2020-05-05
AU2013251558B2 (en) 2019-01-03
AU2013251558A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
IN2014DN09261A (en)
EP3617309A3 (en) Crispr-based genome modification and regulation
PH12012501491B1 (en) Targeted genomic alteration
EP3441468A3 (en) Delivery methods and compositions for nuclease-mediated genome engineering
EP4286517A3 (en) Therapeutic uses of genome editing with crispr/cas systems
WO2013188522A3 (en) Methods and compositions for generating conditional knock-out alleles
MX351043B (en) Methods for genomic modification.
WO2014153470A3 (en) Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
IN2014DN08812A (en)
EP3057432A4 (en) Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3313991A4 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2014033644A3 (en) Methods of nuclease-based genetic engineering
WO2015073683A3 (en) Nuclease-mediated regulation of gene expression
MX388784B (en) METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
WO2012166425A3 (en) Methods of amplifying whole genome of a single cell
EP4234703A3 (en) Genome engineering
MX364662B (en) Optimal maize loci.
MX369747B (en) Targeted modification of rat genome.
SG10201810110RA (en) Extreme pcr
SG10201809901SA (en) Generating Pluripotent Cells De Novo
EA201591445A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING THE EFFICIENCY OF DIRECTED MODIFICATION OF GENES WITH THE APPLICATION OF MEDIATED OLIGONUCLEOTIDE REPAIR GENES
NZ705742A (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
MX2016005874A (en) Optimal soybean loci.
IN2015DN01480A (en)